Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Daily News

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

Caitlin E. Cox

July 21, 2025

News Daily News

Prepregnancy CV Health Portends Midlife Risks: CARDIA Analysis

L.A. McKeown

June 27, 2025

News Daily News

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Michael O'Riordan

June 25, 2025

News Daily News

Amylin Analogue Boosts Weight Loss When Added to GLP-1

L.A. McKeown

June 24, 2025

News Daily News

Majority of US Adults Have High Long-term Risk of CVD: NHANES

Michael O'Riordan

June 13, 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Michael O'Riordan

May 13, 2025

News Conference News HRS 2025

GLP-1 Drugs May Have Role in Secondary Prevention of AF

Todd Neale

April 28, 2025

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

L.A. McKeown

April 18, 2025

News Daily News

Weekend Warriors Also See Mortality Benefits With Exercise

Michael O'Riordan

April 10, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

News Opinion CV Team Dispatch

March 2025 Dispatch for the CV Team

L.A. McKeown

March 21, 2025

News Daily News

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

Caitlin E. Cox

February 26, 2025

News Daily News

CVD Hospitalization in Older Adults Higher in US Than in Denmark

Michael O'Riordan

February 07, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Features

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Michael O'Riordan

January 17, 2025

News Daily News

Global Study Shows Sugary Drinks Boosting Diabetes and CVD at Alarming Rates

L.A. McKeown

January 10, 2025

Advertisement

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

Prepregnancy CV Health Portends Midlife Risks: CARDIA Analysis

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Amylin Analogue Boosts Weight Loss When Added to GLP-1

Majority of US Adults Have High Long-term Risk of CVD: NHANES

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

GLP-1 Drugs May Have Role in Secondary Prevention of AF

April 2025 Dispatch for the CV Team

Weekend Warriors Also See Mortality Benefits With Exercise

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

March 2025 Dispatch for the CV Team

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

CVD Hospitalization in Older Adults Higher in US Than in Denmark

January 2025 Dispatch for the CV Team

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Global Study Shows Sugary Drinks Boosting Diabetes and CVD at Alarming Rates

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content